shutterstock_639337048_jonathan_weiss
Jonathan Weiss / Shutterstock.com
7 November 2019Big PharmaSaman Javed

Second Circuit dismisses antitrust claims against Roche

The US Court of Appeals for the Second Circuit has dismissed a Russian pharmaceutical company’s antitrust claims against Roche.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
31 October 2019   Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.

More on this story

Big Pharma
31 October 2019   Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.

More on this story

Big Pharma
31 October 2019   Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.